BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Biotech catalysts in 2026-06
255 industry Phase 2/3 trial readout(s) and 40 FDA decision event(s). Readouts include completed (ACTUAL) and still-estimated primary completion dates in this month, any status.
FDA decision events
Trial readouts
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-06 est. | P2 | Sound Pharmaceuticals, Incorporated SOGP | NCT01451853 SPI-1005 for Prevention and Treatment of Chemotherapy Induced Hearing Loss | Lung Cancer; Head and Neck Cancer; Hearing Loss; Ototoxicity; Tinnitus; Neuropathy | withdrawn | |
| 2026-06 est. | P2 | Sound Pharmaceuticals, Incorporated SOGP | NCT02779192 A Phase 2b Study of SPI-1005 to Prevent Acute Noise Induced Hearing Loss | Noise Induced Hearing Loss | withdrawn | |
| 2026-06 est. | P2 | Actuate Therapeutics Inc. ACTU | NCT03678883 9-ING-41 in Patients With Advanced Cancers | Cancer; Pancreatic Cancer; Sarcoma; Renal Cancer; Refractory Cancer; Refractory Neoplasm; Refractory | active not recruiting | 350 |
| 2026-06 est. | P3 | Cook MyoSite | NCT03997318 Japanese Bridging Study of Autologous Muscle Derived Cells Compared to Placebo for Female Urinary Sphincter Repair(JPN1) | Stress Urinary Incontinence | withdrawn | |
| 2026-06 est. | P2 | Pharmazz, Inc. | NCT04054414 PMZ-1620 (Sovateltide) in Patients of Acute Spinal Cord Injury | Acute Spinal Cord Injury | recruiting | 40 |
| 2026-06 est. | P1/P2 | Rakuten Medical, Inc. | NCT04305795 An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors | Recurrent Head and Neck Squamous Cell Carcinoma; Metastatic Head-and-neck Squamous-cell Carcinoma; L | active not recruiting | 23 |
| 2026-06 est. | P1/P2 | 4D Molecular Therapeutics FDMT | NCT04517149 4D-125 in Patients With X-Linked Retinitis Pigmentosa (XLRP) | X-Linked Retinitis Pigmentosa | active not recruiting | 21 |
| 2026-06 est. | P2 | Y-mAbs Therapeutics | NCT04909515 Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GMCSF) and Isotretinoin for Consolidation of Patients With High-Risk Neuroblastoma in First Remi | Neuroblastoma | withdrawn | |
| 2026-06 est. | P1/P2 | Verastem, Inc. VSTM | NCT05074810 Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients | Non Small Cell Lung Cancer; KRAS Activating Mutation | active not recruiting | 153 |
| 2026-06 est. | P1/P2 | CG Pharmaceuticals, Inc | NCT05249101 A Study of Ivaltinostat Plus Capecitabine or Capecitabine in Metastatic Pancreatic Adenocarcinoma | Metastatic Pancreatic Adenocarcinoma | active not recruiting | 70 |
| 2026-06 est. | P2 | Clene Nanomedicine CLNN | NCT05299658 An Open-Label Extension for the Phase 2 Study in Early Symptomatic Amyotrophic Lateral Sclerosis Patients on Stable Background Therapy to Assess Bioenergetic Ca | Amyotrophic Lateral Sclerosis | active not recruiting | 40 |
| 2026-06 est. | P3 | Probelte Pharma S.L.U. | NCT05395689 Efficacy and Safety Assessment of Beltavac® With Polymerized Extract of HDM | House Dust Mite Allergy | unknown | 350 |
| 2026-06 est. | P1/P2 | Advanced BioDesign | NCT05601726 First-in-human Study Aiming to Characterize the Safety, Tolerability, Pharmacokinetic and Preliminary Signs of Activity of ABD-3001 in Refractory or Relapsed AM | Acute Myeloid Leukemia, Adult; Myelodysplastic Syndromes | recruiting | 36 |
| 2026-06 est. | P1/P2 | InSightec | NCT05615623 Blood Brain Barrier (BBB) Disruption Using Exablate Focused Ultrasound With Doxorubicin for Treatment of Pediatric DIPG | Brain Tumor | active not recruiting | 10 |
| 2026-06 est. | P1/P2 | 4D Molecular Therapeutics FDMT | NCT05629559 4D-310 in Adults With Fabry Disease and Cardiac Involvement | Fabry Disease | recruiting | 18 |
| 2026-06 est. | P1/P2 | InSightec | NCT05630209 Blood Brain Barrier (BBB) Disruption Using Exablate Focused Ultrasound With Doxorubicin for Treatment of Pediatric Diffuse Intrinsic Pontine Gliomas (DIPG) | Brain Tumor | active not recruiting | 10 |
| 2026-06 est. | P2 | Vaneltix Pharma, Inc. | NCT05737121 Safety and Efficacy Study of VNX001 Compared to Its Individual Components (Lidocaine and Heparin) or Placebo in Subjects With IC/BPS | Interstitial Cystitis; Bladder Pain Syndrome | recruiting | 120 |
| 2026-06 est. | P1/P2 | 1ST Biotherapeutics, Inc. | NCT05761223 A Phase I/II, Open-label Study to Investigate the Safety, Tolerability, PK, and Preliminary Efficacy of FB849 | Advanced Solid Tumor | recruiting | 151 |
| 2026-06 est. | P3 | RemeGen Co., Ltd. | NCT05799287 A Study of Telitacicept for IgA Nephropathy (TELIGAN) | Primary IgA Nephropathy | active not recruiting | 318 |
| 2026-06 est. | P3 | RemeGen Co., Ltd. | NCT05885503 Efficacy and Safety of RC28-E Versus Aflibercept in Diabetic Macular Edema | Diabetic Macular Edema | unknown | 316 |
| 2026-06 est. | P1/P2 | Volastra Therapeutics, Inc. | NCT05902988 A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer | Advanced Solid Tumor; High Grade Serous Adenocarcinoma of Ovary; Squamous Non-small-cell Lung Cancer | recruiting | 200 |
| 2026-06 est. | P2 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | NCT05913089 A Clinical Study of TQB2450 Injection Combined With Chemotherapy or Anlotinib Hydrochloride Capsule in the Treatment of Non Small Cell Lung Cancer | Non Small Cell Lung Cancer | recruiting | 58 |
| 2026-06 est. | P1/P2 | Juventas Cell Therapy Ltd. | NCT06005649 Clinical Trial of HY004 Cell Injection in the Treatment of Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma | Non-hodgkin Lymphoma | withdrawn | |
| 2026-06 est. | P2 | Q32 Bio Inc. QTTB | NCT06018428 A Phase 2a Proof-of-Concept Trial of Bempikibart (ADX-914) for the Treatment of Severe Alopecia Areata (SIGNAL-AA) | Alopecia Areata | active not recruiting | 75 |
| 2026-06 est. | P2 | ITB-Med LLC | NCT06019507 A Study of TCD601 in the Induction of Tolerance in de Novo Liver Transplantation | Liver Transplantation | active not recruiting | 12 |
| 2026-06 est. | P2 | Lakewood-Amedex Inc LABT | NCT06020235 Nu-3 Gel for Infected Diabetic Foot Ulcers | Diabetic Foot Infection | not yet recruiting | 60 |
| 2026-06 est. | P1/P2 | COUR Pharmaceutical Development Company, Inc. | NCT06106672 Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of CNP-106 in Subjects With Myasthenia Gravis | Myasthenia Gravis; Generalized Myasthenia; AChR Myasthenia Gravis; MuSK MG | active not recruiting | 54 |
| 2026-06 est. | P2/P3 | Sling Therapeutics, Inc. | NCT06112340 Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED) | Thyroid Eye Disease; Graves Orbitopathy; Endocrine System Diseases; Eye Diseases; Thyroid Associated | recruiting | 75 |
| 2026-06 est. | P3 | Qilu Pharmaceutical Co., Ltd. | NCT06151587 A Phase 3 Clinical Study of QLM3004 in Delaying Myopia in Children | Myopia | recruiting | 735 |
| 2026-06 est. | P1/P2 | Shandong Suncadia Medicine Co., Ltd. | NCT06167694 Clinical Study of HRS-8080 in Combination With Dalpiciclib Isethionate Tablets in Patients With Unresectable or Metastatic Breast Cancer | Unresectable or Metastatic Breast Cancer | recruiting | 146 |
| 2026-06 est. | P2 | RemeGen Co., Ltd. | NCT06178159 DV in Combination With Pertuzumab With or Without Toripalimab Neoadjuvant Therapy With HER2-positive Breast Cancer | Breast Cancer | recruiting | 40 |
| 2026-06 est. | P3 | EMS | NCT06264414 Efficacy and Safety of the DTT106 in the Treatment of Erectile Dysfunction Associated With Benign Prostatic Hyperplasia | Prostatic Hyperplasia, Benign; Erectile Dysfunction | not yet recruiting | 262 |
| 2026-06 est. | P2 | Noema Pharma AG | NCT06315751 Efficacy and Safety of Gemlapodect (NOE-105) in Adults and Adolescents With Tourette Syndrome | Tourette Syndrome | active not recruiting | 164 |
| 2026-06 est. | P2 | Philogen S.p.A. | NCT06336291 A Study With L19TNF in Combination With Lomustine in Patients With Glioblastoma at Progression or Recurrence | Glioblastoma | active not recruiting | 90 |
| 2026-06 est. | P2 | BioMarin Pharmaceutical BMRN | NCT06382155 A Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature | Idiopathic Short Stature | recruiting | 100 |
| 2026-06 est. | P1/P2 | GRIN Therapeutics, Inc. | NCT06392009 Astroscape: A Study of Radiprodil on Safety, Tolerability, Pharmacokinetics, and Effect on Seizures and Behavioral Symptoms in Patients With TSC or FCD Type II | Tuberous Sclerosis Complex; Focal Cortical Dysplasia | active not recruiting | 30 |
| 2026-06 est. | P2 | Vaneltix Pharma, Inc. | NCT06394830 Safety, Efficacy, and Frequency of Administration of VNX001 in the Treatment of Interstitial Cystitis / Bladder Pain Syndrome (IC/BPS) | Interstitial Cystitis; Bladder Pain Syndrome | recruiting | 50 |
| 2026-06 est. | P3 | Jiangsu HengRui Medicine Co., Ltd. | NCT06414837 Clinical Trial of HR091506 Tablets in Treatment of Gout With Hyperuricemia in Adults | Gout With Hyperuricemia in Adults | unknown | 434 |
| 2026-06 est. | P2 | AlaMab Therapeutics (Shanghai) Inc. | NCT06416358 A Study to Evaluate the Efficacy of ALMB-0168 in Solid Tumor Patients With Bone Metastatic Whose Prior Standard Treatment Have Failed | Advanced Solid Tumors With Bone Only Metastasis | not yet recruiting | 144 |
| 2026-06 est. | P2 | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | NCT06452706 The Clinical Trial of TQB2102 for Injection Against Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer | Breast Cancer | recruiting | 42 |
| 2026-06 est. | P2 | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | NCT06496490 A Clinical Trial of TQB2102 for Injection in Non-small Cell Lung Cancer With HER2 Gene Abnormality | Non-Small Cell Lung Cancer | recruiting | 270 |
| 2026-06 est. | P2 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | NCT06500091 TQB2916 Injection Combined With Chemotherapy or Penpulimab Injection in the Treatment of Solid Tumors | Soft Tissue Sarcoma; Melanoma | not yet recruiting | 54 |
| 2026-06 est. | P1/P2 | Akeso | NCT06530251 A Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC) | Hepatocellular Carcinoma | recruiting | 280 |
| 2026-06 est. | P3 | Chengdu Kanghong Pharmaceutical Group Co., Ltd. | NCT06589817 A Double-Blind, Randomized Comparative Study of Carliprazine and Aripiprazole in Patients with Acute Schizophrenia | Acute Schizophrenia | not yet recruiting | 376 |
| 2026-06 est. | P3 | Revolution Medicines, Inc. RVMD | NCT06625320 Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) | Pancreatic Cancer; PDAC; PDAC - Pancreatic Ductal Adenocarcinoma | active not recruiting | 500 |
| 2026-06 est. | P2 | Autobahn Therapeutics, Inc. | NCT06633016 Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY) | Major Depressive Disorder | recruiting | 230 |
| 2026-06 est. | P3 | Biocad | NCT06640517 Study of the Efficacy, Safety, Pharmacokinetics, and Immunogenicity of Netakimab in Children With Moderate to Severe Plaque Psoriasis | Plaque Psoriasis | active not recruiting | 140 |
| 2026-06 est. | P3 | Santen Pharmaceutical Co., Ltd. | NCT06683651 A Study in Chinese Patients With Acquired Blepharoptosis | Blepharoptosis | recruiting | 180 |
| 2026-06 est. | P3 | Sagimet Biosciences Inc. SGMT | NCT06692283 A Phase 3 Study Evaluating the Safety and Efficacy of Denifanstat in Patients With MASLD and MASH | MASLD; MASH; NASH; Metabolic Dysfunction-Associated Steatotic Liver Disease; Metabolic Dysfunction-A | withdrawn | |
| 2026-06 est. | P2 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | NCT06702618 Evaluation of TQB3616 Capsules in a Phase II Clinical Trial for Recurrent/Metastatic Breast Cancer | Breast Cancer | active not recruiting | 33 |
| 2026-06 est. | P2 | Qilu Pharmaceutical Co., Ltd. | NCT06750341 Study of QLC7401 in the Treatment of Primary Hypercholesterolemia or Mixed Hyperlipidemia With Elevated LDL Cholesterol | Primary Hypercholesterolemia or Mixed Hyperlipidemia | not yet recruiting | 156 |
| 2026-06 est. | P2 | Mabwell (Shanghai) Bioscience Co., Ltd. | NCT06823427 9MW2821 + Toripalimab vs 9MW2821 for 1st Line Locally Advanced or Metastatic Urothelial Carcinoma | Urothelial Carcinoma; Urothelial Carcinoma Bladder; Urothelial Carcinoma Recurrent; Urothelial Carci | recruiting | 60 |
| 2026-06-01 | P3 | AstraZeneca AZN | NCT03682068 Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable | Unresectable Locally Advanced Urothelial Cancer; Metastatic Urothelial Cancer | active not recruiting | 1246 |
| 2026-06-01 est. | P1/P2 | Intralytix, Inc. | NCT03808103 Safety and Efficacy of EcoActive on Intestinal Adherent Invasive E. Coli in Patients With Inactive Crohn's Disease | Crohn Disease | active not recruiting | 30 |
| 2026-06-01 est. | P1/P2 | BioIntegrate | NCT04711304 Evaluation of Safety and Efficacy of Wharton's Jelly Compared to Hyaluronic Acid and Saline for Knee Osteoarthritis. | Osteoarthritis, Knee | unknown | 168 |
| 2026-06-01 est. | P1/P2 | Alligator Bioscience AB | NCT04888312 Safety and Efficacy of Mitazalimab in Combination With Chemotherapy in Pancreatic Cancer Patients | Metastatic Pancreatic Ductal Adenocarcinoma | active not recruiting | 94 |
| 2026-06-01 est. | P3 | Laboratorio Elea Phoenix S.A. | NCT04897516 Shorter Benznidazole Regimens Compared to the Standard Regimen for Chagas Disease | Chagas Disease | recruiting | 300 |
| 2026-06-01 est. | P2/P3 | Jiangsu HengRui Medicine Co., Ltd. | NCT05442827 A Phase II/III Study of Efficacy and Safety of SHR7280 Tablets in Subjects With Menorrhagia With Uterine Fibroids | Uterine Fibroids With Menorrhagia | unknown | 357 |
| 2026-06-01 est. | P1/P2 | Gylden Pharma Ltd | NCT05633446 Next Generation T-cell Vaccine Against Coronavirus Disease (COVID-19) | Coronavirus; SARS-CoV-2 Infection; COVID-19 | not yet recruiting | 110 |
| 2026-06-01 est. | P2/P3 | Inmunotek S.L. | NCT05641272 Clinical Trial to Evaluate the Efficacy and Safety of Polymerized, Mannan-Conjugated Dermatophagoides Allergen Extract | Allergic Rhinitis; Allergic Asthma; Allergic Rhinoconjunctivitis; Allergy to House Dust Mite | not yet recruiting | 90 |
| 2026-06-01 est. | P1/P2 | ViiV Healthcare | NCT05674656 Pharmacokinetics, Safety, Tolerability of Dolutegravir/Rilpivirine in Pediatrics | HIV Infections | recruiting | 20 |
| 2026-06-01 | P3 | Ipsen | NCT06047457 A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Episodic Migraine in Adults | Episodic Migraine | active not recruiting | 751 |
| 2026-06-01 | P3 | Boehringer Ingelheim | NCT06077864 A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT) | Obesity | completed | 5530 |
| 2026-06-01 est. | P2/P3 | Oncotelic Inc. OTLC | NCT06079346 A Study of OT-101 With mFOLFIRINOX in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer | Pancreatic Ductal Adenocarcinoma | recruiting | 455 |
| 2026-06-01 est. | P3 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | NCT06296706 A Clinical Study of Docetaxel for Injection (Albumin-bound) in Patients With Gastric Cancer | Gastric Cancer | recruiting | 630 |
| 2026-06-01 | P3 | Arrowhead Pharmaceuticals ARWR | NCT06347133 Phase 3 Study of Plozasiran in Adults With Hypertriglyceridemia | Hypertriglyceridemia | completed | 1456 |
| 2026-06-01 est. | P2/P3 | Hansoh BioMedical R&D Company | NCT06417008 A Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer | Non-Squamous Non-Small Cell Lung Cancer | recruiting | 1080 |
| 2026-06-01 est. | P2 | Arcturus Therapeutics, Inc. ARCT | NCT06488313 A Study to Evaluate the Pharmacodynamics and Safety of ARCT-810 in Participants With OTCD | OTC Deficiency; Ornithine Transcarbamylase Deficiency; OTCD | recruiting | 9 |
| 2026-06-01 | P1/P2 | Dimagi Inc. | NCT06845878 A Chatbot To Support Substance Use Recovery | Opiate-Related Disorders; Opiate Substitution Treatment | completed | 55 |
| 2026-06-01 est. | P2/P3 | SFA Therapeutics | NCT06863493 Comparison of Otezla to SFA-002 to Placebo in Plaque Psoriasis Patients | Psoriasis (PsO) | not yet recruiting | 125 |
| 2026-06-01 est. | P1/P2 | CASI pharmaceuticals, Inc. CASIF | NCT07017725 A Dose-escalation Study Followed by a Dose Optimal Study to Evaluate the Safety and Efficacy of CID-103 in Adults With Chronic Immune Thrombocytopenia | Chronic Immune Thrombocytopenia | recruiting | 75 |
| 2026-06-01 est. | P1/P2 | Eluciderm Inc | NCT07396376 Evaluation of ELU42 Topical Spray for the Treatment of Diabetic Foot Ulcers | Diabetic Foot Ulcer; Wagner Grade 1 - 2; Chronic Wound; Open Wound | recruiting | 15 |
| 2026-06-01 est. | P3 | Oils4Cure | NCT07403266 Treatment With Full-spectrum Cannabis Extract of Refractory Epilepsy Associated With Tuberous Sclerosis Complex (TSC) | Tuberous Sclerosis Complex (TSC) | recruiting | 84 |
| 2026-06-01 | P3 | Colgate Palmolive CL | NCT07442136 Clinical Study to Assess the Efficacy of New Toothpaste Containing SnF as Compared to Colgate Cavity Protection Toothpaste on the Reduction of Enamel Erosion | Enamel Erosion | completed | 80 |
| 2026-06-01 est. | P2 | Intra-IMMUSG Pte Ltd | NCT07541001 PRL3-Zumab in Patients With Advanced Solid Tumors | Advanced Malignant Solid Tumor | active not recruiting | 60 |
| 2026-06-02 | P1/P2 | Binhui Biopharmaceutical Co., Ltd. | NCT04386967 OH2 Injection in Solid Tumors | Solid Tumor; Melanoma | completed | 44 |
| 2026-06-02 | P3 | Swedish Orphan Biovitrum | NCT05817812 A Study Evaluating Physical Activity and Joint Health in Severe Haemophilia A Patients ≥12 Years Treated Once Weekly With Efanesoctocog Alfa | Hemophilia A, Severe | completed | 93 |
| 2026-06-02 | P1/P2 | Sensei Biotherapeutics, Inc. | NCT05864144 A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors | Solid Tumor, Adult; Advanced Solid Tumor; Head and Neck Cancer; Breast Cancer; Colon Cancer; Pancrea | completed | 98 |
| 2026-06-02 | P3 | Eli Lilly and Company LLY | NCT06075667 A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity or Overweight With Weight-Related Comorbidities | Obesity; Overweight | active not recruiting | 160 |
| 2026-06-02 | P3 | Novo Nordisk A/S NVO | NCT06534411 A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGL | Diabetes Mellitus, Type 2 | completed | 1023 |
| 2026-06-03 | P3 | Hoffmann-La Roche | NCT04712097 A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a | Relapsed or Refractory Follicular Lymphoma | active not recruiting | 478 |
| 2026-06-03 | P2 | Kyowa Kirin Co., Ltd. | NCT06116890 Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration | Neovascular Age-Related Macular Degeneration (nAMD) | completed | 170 |
| 2026-06-03 est. | P1/P2 | Ikaria Bioscience Pty Ltd | NCT06471543 Study of RN0361in Adult Healthy Subjects and Adult Hypertriglyceridemic Subjects | Hypertriglyceridemia; Familial Chylomicronemia Syndrome | active not recruiting | 108 |
| 2026-06-04 | P2 | MapLight Therapeutics MPLT | NCT07038876 A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With Schizophrenia | Schizophrenia | completed | 307 |
| 2026-06-04 | P2 | Fulcrum Therapeutics FULC | NCT07401823 Open-Label Extension Study to Pioneer Study 6058-SCD-101 | Sickle Cell Disease | terminated | 1 |
| 2026-06-05 | P3 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | NCT06640257 A Study of the Efficacy and Safety of SHR-1314 for Adult Active Psoriatic Arthritis | Psoriatic Arthritis | active not recruiting | 208 |
| 2026-06-05 | P2 | Merck Sharp & Dohme LLC MRK | NCT06721156 A Study to Evaluate the Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia (MK-1167-008) | Alzheimer Disease; Dementia | terminated | 369 |
| 2026-06-05 est. | P2 | Haisco Pharmaceutical Group Co., Ltd. | NCT06902428 Evaluating the Efficacy and Safety of of HSK44459 in Patients With Behçet's Disease | Behcet's Disease | not yet recruiting | 120 |
| 2026-06-05 | P3 | Merz North America, Inc. | NCT07122193 A Study of NT 201 in Adults With Moderate to Severe Platysma Prominence in the United States | Neuromuscular Agents; Peripheral Nervous System Agents; Physiological Effects of Drugs; Acetylcholin | active not recruiting | 300 |
| 2026-06-06 | P3 | Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd. | NCT07080931 Efficacy and Safety of 5% Minoxidil Foam in Female Androgenetic Alopecia | Androgenetic Alopecia | completed | 296 |
| 2026-06-06 | P3 | Colgate Palmolive CL | NCT07471477 Bacterial Reduction for a Manual Toothbrush With a 360-Degree Mouth Cleaner Design Versus a Standard Toothbrush | Bacterial Load Reduction | completed | 56 |
| 2026-06-07 est. | P3 | Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. | NCT06945107 A Study of Switching to Picankibart in Chinese Patients With Plaque Psoriasis With an Inadequate Response to Interleukin-17 Monoclonal Antibody Therapy | Plaque Psoriasis | active not recruiting | 308 |
| 2026-06-07 est. | P2 | Shanghai Argo Biopharmaceutical Co., Ltd. | NCT07135349 A Phase II Clinical Study of BW-20507 in Combination With PEG-IFNα for the Treatment of Hepatitis B | Chronic Hepatitis B | active not recruiting | 209 |
| 2026-06-08 | P2 | Merck Sharp & Dohme LLC MRK | NCT04123366 Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Re | Solid Tumors | completed | 333 |
| 2026-06-08 | P2 | Dizal Pharmaceuticals | NCT06295432 A Phase II Clinical Trial of DZD9008 in Combination With AZD4205 in Standard Treatment Failed NSCLC Patients With EGFR Mutations (WU-KONG21) | Non-small Cell Lung Cancer | completed | 30 |
| 2026-06-08 est. | P2 | Regeneron Pharmaceuticals REGN | NCT06384820 Study of Cemiplimab Alone or in Combination With Fianlimab and/or Other Experimental Agents in Adult Participants With Peri-operative Stage III/IV Cutaneous Squ | Cutaneous Squamous Cell Carcinoma | withdrawn | |
| 2026-06-08 | P3 | Sanofi SNY | NCT06687967 A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injections Compared With Placebo in Male and Female Participants Aged | Lichen Simplex Chronicus | completed | 142 |
| 2026-06-08 | P3 | Sanofi SNY | NCT06687980 A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injections Compared With Placebo in Male and Female Participants Aged | Lichen Simplex Chronicus | completed | 138 |
| 2026-06-08 | P1/P2 | Nanjing Immunophage Biotech Co., Ltd | NCT06717815 Phase IIa Study for IPG11406 in Patients With Lupus Nephritis | Lupus Nephritis | completed | 24 |
| 2026-06-09 | P3 | Novo Nordisk A/S NVO | NCT05021835 ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation | Cardiovascular Risk; Chronic Kidney Disease; Inflammation | completed | 6385 |
| 2026-06-09 | P3 | AstraZeneca AZN | NCT05048797 A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small C | Locally Advanced or Metastatic Non-Small Cell Lung Cancer | active not recruiting | 454 |
| 2026-06-09 est. | P2 | Novartis Pharmaceuticals NVS | NCT05750628 Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Patients With Uncomplicated Plasmodium Falciparum Malaria | Uncomplicated Plasmodium Falciparum Malaria | recruiting | 327 |
| 2026-06-09 | P3 | Endo USA Inc., a Keenova Therapeutics Company | NCT06151197 Study to Assess EN3835 in the Treatment of Plantar Fibromatosis (Also Known as Ledderhose Disease) | Plantar Fibromatosis; Ledderhose Disease | completed | 436 |
| 2026-06-10 | P1/P2 | Novartis Pharmaceuticals NVS | NCT03945318 Safety and Tolerability of BION-1301 in Healthy Volunteers and Adults With IgA Nephropathy (IgAN) | IgA Nephropathy | completed | 103 |
| 2026-06-10 | P3 | SK Life Science, Inc. | NCT03961568 Cenobamate Open-Label Extension Study for YKP3089C025 | Primary Generalized Tonic Clonic Seizures in the Setting of Idiopathic Generalized Epilepsy | completed | 147 |
| 2026-06-10 | P3 | Bellus Health Inc. - a GSK company | NCT05600777 A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough | Cough; Refractory Chronic Cough | active not recruiting | 997 |
| 2026-06-10 | P2 | Genmab GMAB | NCT05660967 Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma | Diffuse Large B-Cell Lymphoma | terminated | 111 |
| 2026-06-10 | P2/P3 | TWi Biotechnology, Inc. | NCT06073132 An International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study With Open-Label Extension Evaluating the Efficacy a | Generalized Epidermolysis Bullosa Simplex | active not recruiting | 80 |
| 2026-06-10 | P3 | Sanofi SNY | NCT06290128 A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do | Chronic Inflammatory Demyelinating Polyradiculoneuropathy; Polyneuropathy, Inflammatory Demyelinatin | active not recruiting | 109 |
| 2026-06-10 | P3 | Sanofi SNY | NCT06407934 A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 1 | Dermatitis Atopic | active not recruiting | 1541 |
| 2026-06-10 | P2 | Dizal Pharmaceuticals | NCT06539195 DZD8586 in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (TAI-SHAN9) | Diffuse Large B Cell Lymphoma | completed | 59 |
| 2026-06-10 | P3 | Kedrion S.p.A. | NCT06963216 A Study Investigating Coagadex in the Treatment AFXD Associated With AL Amyloidosis | Acquired Factor X Deficiency | withdrawn | |
| 2026-06-11 | P3 | Cook MyoSite | NCT03104517 Autologous Muscle Derived Cells Compared to Placebo for Urinary Sphincter Repair in Post-surgical Female Stress Incontinence | Stress Urinary Incontinence | active not recruiting | 96 |
| 2026-06-11 | P3 | HTA Co., Ltd. | NCT06754085 Study of 18F-Florastamin PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer | Prostate Cancer | completed | 131 |
| 2026-06-12 | P2 | Beeline Medicines Corporation BLNE | NCT04895696 A Study Evaluating the Efficacy and Safety of Afimetoran Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE) | Systemic Lupus Erythematosus | active not recruiting | 248 |
| 2026-06-12 | P3 | Arrowhead Pharmaceuticals ARWR | NCT06347003 Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia | Severe Hypertriglyceridemia | completed | 446 |
| 2026-06-12 | P3 | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | NCT06516302 A Study of GR1802 in Participants With Chronic Sinusitis With Nasal Polyps | Chronic Rhinosinusitis With Nasal Polyps | completed | 228 |
| 2026-06-12 | P2 | Ono Pharmaceutical Co., Ltd. | NCT06752603 A Clinical Study of ONO-1110 in Patients With Hunner Type Interstitial Cystitis | Hunner Type Interstitial Cystitis | completed | 57 |
| 2026-06-12 | P2 | VistaGen Therapeutics, Inc. VTGN | NCT06809179 A Clinical Trial to Assess the Efficacy, Safety, and Tolerability of a Repeat Dose of Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With S | Social Anxiety Disorder | completed | 61 |
| 2026-06-12 est. | P2/P3 | Nasus Pharma NSRX | NCT07045701 FMXIN002 in Patients at Risk of Anaphylaxis | Anaphylaxis Food | enrolling by invitation | 30 |
| 2026-06-12 | P2 | Shaanxi Micot Pharmaceutical Technology Co., Ltd. | NCT07205328 A Clinical Trial of MT200605 for the Treatment of Acute Ischemic Stroke | Acute Ischemic Stroke | completed | 360 |
| 2026-06-12 | P3 | TLC Biopharmaceuticals, Inc. | NCT07222748 A Study of TLC590 for Postsurgical Pain Following Bunionectomy | Postoperative Pain | active not recruiting | 304 |
| 2026-06-14 | P2 | Reconnect Labs | NCT06685965 A Study to Evaluate Effects on Sleep and Safety of RE03 in PTSD Patients With Sleep Disturbances | Posttraumatic Stress Disorder (PTSD); Sleep Disturbances and Insomnia | completed | 12 |
| 2026-06-15 | P3 | Merck Sharp & Dohme LLC MRK | NCT05298423 Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemora | Carcinoma, Non-Small-Cell Lung | completed | 610 |
| 2026-06-15 | P1/P2 | Verastem, Inc. VSTM | NCT05375994 Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC Patients | Non Small Cell Lung Cancer; KRAS Activating Mutation; Advanced Cancer; Metastatic Cancer; Malignant | completed | 12 |
| 2026-06-15 | P1/P2 | T-ACE Medical Co., Ltd | NCT05435014 T-ACE Oil by TAE/TACE in Patients With Hepatocellular Carcinoma | Hepatocellular Carcinoma | terminated | 2 |
| 2026-06-15 est. | P2 | Jiangsu HengRui Medicine Co., Ltd. | NCT05896020 A Study of SHR-A1811 in Subjects With Gynaecologic Oncology | Gynaecological Malignancies | unknown | 225 |
| 2026-06-15 | P2 | Shionogi | NCT05953480 A Phase 2b, Randomized, Double-blind Study of Redasemtide (S-005151) in Adult Participants With Acute Ischemic Stroke | Acute Ischemic Stroke | completed | 680 |
| 2026-06-15 est. | P2/P3 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | NCT06211023 A Study of SHR-A1921 With or Without Carboplatin in Subjects With Ovarian Cancer | Ovarian Cancer | unknown | 520 |
| 2026-06-15 est. | P2 | Nocion Therapeutics | NCT06504446 Study to Assess the Efficacy, Safety, and Tolerability of NOC-110 in Adults With Refractory or Unexplained Chronic Cough | Refractory or Unexplained Chronic Cough | active not recruiting | 455 |
| 2026-06-15 est. | P2 | Wuhan Createrna Science and Technology Co., Ltd | NCT06687174 Study to Evaluate the Efficacy and Safety of MY008211A in Subjects with Primary Immunoglobulin a Nephropathy (IgAN) | IgA Nephropathy (IgAN) | not yet recruiting | 72 |
| 2026-06-15 | P2 | CyanVac LLC | NCT06742281 A Phase 2b, Randomized, Double-blind, Active-controlled Study of Single Dose CVXGA Intranasal COVID-19 Vaccine in Adults | COVID-19 | completed | 432 |
| 2026-06-15 est. | P3 | Guangdong Raynovent Biotech Co., Ltd | NCT06893016 Evaluation of RAY1225 in Adult Participants Who Have Obesity or Are Overweight | Obesity | recruiting | 640 |
| 2026-06-15 est. | P2 | Sinovac Life Sciences Co., Ltd. | NCT06967272 PhaseⅡClinical Trial of Oral Hexavalent Reassortant Rotavirus Attenuated Live Vaccine (Vero Cells) | Rotavirus Gastroenteritis | recruiting | 400 |
| 2026-06-15 est. | P2 | Aspargo Labs, Inc | NCT07290400 Effect of Moderate Alcohol on Absorption and Onset of Hezkue Sildenafil Suspension | Erectile Dysfunction | not yet recruiting | 36 |
| 2026-06-16 | P2 | Hanmi Pharmaceutical Company Limited HAFC | NCT04732416 HM15136 (Efpegerglucagon) Treatment for 8 Weeks in Subjects Aged ≥2 Years With Congenital Hyperinsulinism (CHI) | Congenital Hyperinsulinism | active not recruiting | 17 |
| 2026-06-16 | P3 | Exelixis EXEL | NCT05425940 Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer | Colorectal Cancer | active not recruiting | 901 |
| 2026-06-16 est. | P2 | Guangdong Raynovent Biotech Co., Ltd | NCT05692492 A Randomized, Double-blind, Placebo-controlled Study of ZSP1601 in Adult Subjects With Nonalcoholic Steatohepatitis (NASH) | Nonalcoholic Steatohepatitis (NASH) | active not recruiting | 180 |
| 2026-06-16 | P3 | Eli Lilly and Company LLY | NCT05929079 A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight | Type 2 Diabetes; Obesity; Overweight; Obstructive Sleep Apnea | completed | 1152 |
| 2026-06-16 | P2 | Regeneron Pharmaceuticals REGN | NCT06299098 A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weig | Obesity | completed | 1005 |
| 2026-06-16 | P3 | Ipsen | NCT06383403 A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. | Primary Biliary Cholangitis | completed | 92 |
| 2026-06-16 | P1/P2 | Kyverna Therapeutics KYTX | NCT06400303 KYSA-5: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Systemic Sclerosis | Systemic Sclerosis; Systemic Sclerosis - Diffuse Cutaneous; Systemic Sclerosis - 2013 ACR/EULAR Clas | terminated | 3 |
| 2026-06-17 | P1/P2 | Precision Biologics, Inc DTIL | NCT03476681 Study of NEO-201 in Solid Tumors Expansion Cohorts | Non Small Cell Lung Cancer; Head and Neck Squamous Cell Carcinoma; Cervical Cancer; Uterine Cancer | active not recruiting | 121 |
| 2026-06-17 | P2 | Regeneron Pharmaceuticals REGN | NCT03888105 A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Ot | B-cell Non-Hodgkin Lymphoma (B-NHL) | active not recruiting | 515 |
| 2026-06-17 | P3 | Ionis Pharmaceuticals, Inc. IONS | NCT04768972 FUSION: A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ION363 in Amyotrophic Lateral Sclerosis Participants With Fused in Sa | Amyotrophic Lateral Sclerosis | active not recruiting | 89 |
| 2026-06-17 | P3 | Arrowhead Pharmaceuticals ARWR | NCT06347016 Study of Plozasiran in Adults With Severe Hypertriglyceridemia | Severe Hypertriglyceridemia | completed | 311 |
| 2026-06-17 | P2 | SoLa Pelvic Therapy | NCT06673108 Vaginal Photobiomodulation for Chronic Pelvic Pain | Chronic Pelvic Pain; Chronic Pelvic Pain Syndrome (CPPS) | completed | 128 |
| 2026-06-17 | P3 | Bayer | NCT06904274 Mirena for the Treatment of Nonatypical Endometrial Hyperplasia for 6 Months | Endometrial Hyperplasia | withdrawn | |
| 2026-06-17 | P3 | Hansoh BioMedical R&D Company | NCT06935409 Study of HS-20093 Versus Gemcitabine in Combination With Docetaxel in Treatment of Osteosarcoma After Previous Second-line Treatment Failure | Osteosarcoma | completed | 122 |
| 2026-06-17 | P1/P2 | Capsida Biotherapeutics, Inc. | NCT07011771 A Clinical Trial of CAP-003 Gene Therapy in Adult Patients With GBA1 Associated Parkinson's Disease | GBA1 Parkinson Disease | withdrawn | |
| 2026-06-17 | P3 | Shanghai Shengdi Pharmaceutical Co., Ltd | NCT07275814 A Study of a Gadolinium-Based Contrast Agent (GBCA) for Adults Undergoing Magnetic Resonance Imaging (MRI) for Known or Highly Suspected Central Nervous System | For Contrast-enhanced Magnetic Resonance Imaging (MRI) of Central Nervous System (CNS) Lesions | completed | 250 |
| 2026-06-17 | P2 | Novartis Pharmaceuticals NVS | NCT07811882 Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria (Cohort B1) | Uncomplicated Plasmodium Falciparum Malaria | completed | 95 |
| 2026-06-18 | P2 | AbbVie ABBV | NCT04567550 RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Diabetic Retinopathy (DR) With and Without Center Involved-Diabetic Macular | Diabetic Retinopathy (DR); Center-Involved Diabetic Macular Edema (CI-DME) | completed | 139 |
| 2026-06-18 | P3 | Taiho Pharmaceutical Co., Ltd. | NCT04587908 A Phase 3 Study of TAS-205 in Patients With Duchenne Muscular Dystrophy(REACH-DMD) | Duchenne Muscular Dystrophy | completed | 104 |
| 2026-06-18 | P3 | Atea Pharmaceuticals, Inc. AVIR | NCT06868264 C-BEYOND: Efficacy and Safety of BEM/RZR vs. SOF/VEL in Subjects With Chronic HCV | HEPATITIS C VIRUS CHRONIC INFECTION | completed | 940 |
| 2026-06-18 | P2 | Zhejiang Doer Biologics Co., Ltd. | NCT07024212 Phase II Study Evaluating the Efficacy and Safety of DR10624 Injection in MASLD and MetALD Subjects | MASLD | active not recruiting | 110 |
| 2026-06-19 | P3 | AbbVie ABBV | NCT03891446 Long-term Safety and Efficacy Extension Trial of Bimatoprost SR | Open-Angle Glaucoma; Ocular Hypertension | completed | 455 |
| 2026-06-19 | P1/P2 | Passage Bio, Inc. PASG | NCT04747431 A Study of PBFT02 in Participants With FTD and Mutations in the Granulin Precursor (GRN) or C9ORF72 Genes | Frontotemporal Dementia; FTD; FTD-GRN; Dementia Frontotemporal; C9orf72 | terminated | 30 |
| 2026-06-19 | P2 | Pfizer PFE | NCT05217446 A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorecta | Metastatic Colorectal Cancer | active not recruiting | 108 |
| 2026-06-19 | P2 | Celgene | NCT06425302 A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma | Lymphoma, Follicular | active not recruiting | 95 |
| 2026-06-20 est. | P1/P2 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | NCT05055791 A Study to Evaluate the Safety and Tolerance of SYHX1903 in Patients With Relapsed/Refractory Hematologic Malignancies | Acute Myeloid Leukemia; Lymphoma; Multiple Myeloma | unknown | 312 |
| 2026-06-20 | P2 | Agomab Spain S.L.U. | NCT05843578 STENOVA - A Study to Evaluate Safety, Tolerability, PK and PD of AGMB-129 in Patients With Fibrostenotic Crohn's Disease | Fibrostenotic Crohn's Disease | completed | 103 |
| 2026-06-20 est. | P3 | Alebund Pharmaceuticals | NCT06933472 A Study of a Novel Iron-based Phosphate Binder AP301 in Patients With Hyperphosphatemia in the U.S. and China | Hyperphosphatemia; Chronic Kidney Disease, Receiving Dialysis; ESRD (End-Stage Renal Disease); Dialy | recruiting | 264 |
| 2026-06-22 est. | P2 | Cellectar Biosciences, Inc. CLRB | NCT02952508 Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom | Waldenstrom Macroglobulinemia; Multiple Myeloma; Chronic Lymphocytic Leukemia; Small Lymphocytic Lym | active not recruiting | 120 |
| 2026-06-22 | P3 | Albireo, an Ipsen Company | NCT04336722 Efficacy and Safety of Odevixibat in Children With Biliary Atresia Who Have Undergone a Kasai HPE (BOLD) | Biliary Atresia | completed | 254 |
| 2026-06-22 est. | P2/P3 | Alexion Pharmaceuticals, Inc. | NCT05346354 Efficacy and Safety Study of Ravulizumab IV in Pediatric Participants With NMOSD | Neuromyelitis Optica Spectrum Disorder | active not recruiting | 12 |
| 2026-06-22 | P2 | Biocomposites Ltd | NCT05539963 A Feasibility Trial to Investigate the Safety and Between-group Effect Size of STIMULAN VG and Standard of Care (SoC) in Participants With Diabetic Foot Osteomy | Diabetic Foot Osteomyelitis | completed | 61 |
| 2026-06-22 | P1/P2 | Anaveon AG | NCT06470763 A Study Evaluating ANV600 Single Agent or in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (EXPAND-1) | Advanced Solid Tumor | completed | 63 |
| 2026-06-22 est. | P1/P2 | GlaxoSmithKline | NCT06710847 A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Partic | Neoplasms, Colorectal; Solid Tumor; Colon Cancer; Rectal Cancer; Endometrial Cancer | active not recruiting | 14 |
| 2026-06-22 | P2 | Beijing Continent Pharmaceutical Co, Ltd. | NCT07364448 A Study to Evaluate the Safety of Hydronidone Capsules in Patients With Liver Fibrosis | Chronic Hepatitis B With Hepatic Fibrosis | completed | 411 |
| 2026-06-22 | P2/P3 | Amphastar Pharmaceuticals, Inc. AMPH | NCT07560150 Comparison of the Pharmacokinetics (PK) and Pharmacodynamics (PD) Biosimilarity of Proposed Biosimilar/Interchangeable Rapid-Acting Insulin Aspart (I004) and No | Pharmacokinetics; Pharmacodynamics; Insulin Aspart | completed | 62 |
| 2026-06-23 | P1/P2 | Mirati Therapeutics Inc. | NCT03785249 Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1 | Advanced Cancer; Metastatic Cancer; Malignant Neoplastic Disease | active not recruiting | 731 |
| 2026-06-23 | P2 | Alumis Inc ALMS | NCT05966480 Phase 2 Placebo-Controlled Study to Assess the Safety and Efficacy of ESK-001 in Active Systemic Lupus Erythematosus | SLE | active not recruiting | 408 |
| 2026-06-23 | P2 | Pharming Technologies B.V. PHAR | NCT06549114 Leniolisib for Immune Dysregulation in PIDs | Primary Immunodeficiency Disorders (PIDs) | completed | 13 |
| 2026-06-23 | P2 | Novartis Pharmaceuticals NVS | NCT06643481 A Clinical Trial to Learn About the Effects of VHB937 in People With Amyotrophic Lateral Sclerosis (ALS) | Amyotrophic Lateral Sclerosis (ALS) | active not recruiting | 251 |
| 2026-06-24 | P3 | Diamyd Medical AB | NCT05018585 A Phase III Study to Investigate if the Study Drug Diamyd Can Preserve Insulin Production and Improve Glycemic Control in Patients Newly Diagnosed With Type 1 D | Type 1 Diabetes Mellitus | terminated | 321 |
| 2026-06-24 | P2 | Debiopharm International SA | NCT06395753 A Dose Finding Study of Debio 4228 in Participants With Advanced Prostate Cancer | Prostate Cancer | completed | 55 |
| 2026-06-24 | P3 | Rhythm Pharmaceuticals, Inc. RYTM | NCT06596135 Open-Label Extension Study of Setmelanotide | Obesity Associated With Defects in Leptin-melanocortin Pathway | completed | 28 |
| 2026-06-24 est. | P1/P2 | Sinocelltech Ltd. | NCT06769984 A Study of SCTT11 in Healthy Participants and Participants with Thyroid Eye Disease. | TED | not yet recruiting | 100 |
| 2026-06-24 | P2 | Alexion Pharmaceuticals, Inc. | NCT07037420 ALXN2420 Versus Placebo in Combination With Somatostatin Analogs in Participants With Acromegaly | Acromegaly | terminated | 8 |
| 2026-06-25 | P3 | Astellas Pharma Global Development, Inc. | NCT06440967 A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Women With Breast Cancer Who Are Having Hormone Therapy | Hot Flashes | active not recruiting | 982 |
| 2026-06-25 | P2 | Kyverna Therapeutics KYTX | NCT06588491 KYSA-8: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Treatment Refractory Stiff Person Syndrome | Stiff-Person Syndrome; SPS | completed | 27 |
| 2026-06-25 | P2 | Janssen Research & Development, LLC | NCT06785012 A Study to Explore the Efficacy of JNJ-89495120 in the Treatment of Major Depressive Disorder | Depressive Disorder, Major | completed | 105 |
| 2026-06-25 | P2 | Hangzhou PhecdaMed Co., Ltd. | NCT07018245 Clinical Trial of TJ0113 Capsules in the Treatment of Patients With Depressive Disorder | Depression | completed | 149 |
| 2026-06-25 | P2 | Sionna Therapeutics Inc. SION | NCT07108153 Proof-of-concept Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of SION-719 When Added to Trikafta | Cystic Fibrosis (CF) | completed | 15 |
| 2026-06-26 | P2 | Hanmi Pharmaceutical Company Limited HAFC | NCT04505436 Efocipegtrutide (HM15211) in Adults With Biopsy-Confirmed Nonalcoholic Steatohepatitis (NASH) | NASH - Nonalcoholic Steatohepatitis | completed | 215 |
| 2026-06-26 | P3 | AstraZeneca AZN | NCT04711252 A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Receiv | ER-Positive HER2-Negative Breast Cancer | active not recruiting | 1371 |
| 2026-06-26 | P2 | ZetrOZ, Inc. | NCT06257537 Sustained Acoustic Medicine for Symptomatic Treatment of Knee Pain Related to Osteoarthritis | Osteo Arthritis Knee; Arthritis | completed | 307 |
| 2026-06-26 | P2 | Novo Nordisk A/S NVO | NCT06797869 A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy | Diabetes Mellitus, Type 2; Diabetic Peripheral Neuropathy | completed | 142 |
| 2026-06-26 | P3 | Sinovac Biotech Co., Ltd SVA | NCT07211152 Influenza Vaccine (Split Virion), Inactivated, Quadrivalent in Pregnant Women | Influenza | completed | 150 |
| 2026-06-28 est. | P3 | EMS | NCT05640232 Efficacy and Safety of CDE100 in the Treatment of Menstrual Cramp Pain Associated With Primary Dysmenorrhea | Primary Dysmenorrhea | recruiting | 238 |
| 2026-06-28 est. | P2 | Gan & Lee Pharmaceuticals. | NCT07055386 A Study to Compare the Efficacy and Safety of GZR102 Injection and GZR18 Injection in Type 2 Diabetes Mellitus | Type 2 Diabetes Mellitus (T2DM) | active not recruiting | 90 |
| 2026-06-28 | P3 | Colgate Palmolive CL | NCT07458464 Study to Investigate Toothpaste on Antibacterial Effects in the Different Regions of the Mouth | Plaque; Gingivitis | completed | 95 |
| 2026-06-29 | P3 | AriBio Co., Ltd. | NCT05531526 Phase 3, Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants With Early Alzheimer's Disease (Polari | Alzheimer Disease | active not recruiting | 1535 |
| 2026-06-29 | P3 | Vivacelle Bio | NCT06072430 A Phase III, Open Label, Randomized, Controlled Study of VBI-S in the Treatment of Hypovolemia in Patients With Septic Shock (VBI-S-02) | Septic Shock; Sepsis; Hypovolemia | completed | 39 |
| 2026-06-29 | P2 | Tisento Therapeutics | NCT06402123 A Phase 2b Study of Zagociguat in Patients With MELAS | Mitochondrial Encephalopathy, Lactic Acidosis and Stroke-Like Episodes (MELAS Syndrome) | completed | 43 |
| 2026-06-29 | P3 | AbbVie ABBV | NCT06806293 Study of Oral Atogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | Menstrual Migraine (MM) | active not recruiting | 468 |
| 2026-06-29 | P3 | Takeda TAK | NCT07047521 A Study on a New Tetravalent Dengue Vaccine (TDV) Formulation in Healthy Adults | Dengue Fever | active not recruiting | 496 |
| 2026-06-29 | P3 | Novo Nordisk A/S NVO | NCT07271251 A Research Study to See if Two Different Formulations of Oral Semaglutide Are Equally Safe and Effective in Reducing the Blood Sugar Level in Japanese People Wi | Type 2 Diabetes | completed | 267 |
| 2026-06-30 | P2 | Y-mAbs Therapeutics | NCT03363373 Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow | Neuroblastoma | active not recruiting | 122 |
| 2026-06-30 est. | P2/P3 | Zynerba Pharmaceuticals, Inc. | NCT03802799 Open Label Extension to Assess the Long-Term Safety and Tolerability of ZYN002 in Children and Adolescents With FXS | Fragile X Syndrome | active not recruiting | 476 |
| 2026-06-30 | P2/P3 | Price Vision Group | NCT03922542 Comparison of Standard vs. Accelerated Corneal Crosslinking | Keratoconus; Ectasia Corneal | completed | 508 |
| 2026-06-30 est. | P1/P2 | Beijing InnoCare Pharma Tech Co., Ltd. | NCT04014205 A Study of Tyrosine Kinase Inhibitor Orelabrutinib (ICP-022) in Patients With r/r B-Cell Malignancies | Part 1:r/r B-cell Malignancies; Part 2:B-cell Malignancies | active not recruiting | 81 |
| 2026-06-30 | P1/P2 | Linnaeus Therapeutics, Inc. | NCT04130516 Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab | Solid Tumor, Adult | active not recruiting | 200 |
| 2026-06-30 | P2 | Crinetics Pharmaceuticals Inc. | NCT04261712 A Study to Evaluate the Long-Term Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Advance) | Acromegaly | terminated | 43 |
| 2026-06-30 est. | P3 | United BioPharma UTHR | NCT04406727 UB-421 in Combination With Optimized Background Regimen in Patients With Multi-drug Resistant HIV-1 Infection | HIV-1 Infection | unknown | 50 |
| 2026-06-30 est. | P2 | SynAct Pharma Aps | NCT04456816 A Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Treatment With AP1189 in Patients With iMN and Severe Proteinuria | Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy; Severe Proteinuria Due to Idiopathic Me | recruiting | 23 |
| 2026-06-30 est. | P3 | PharmaEssentia Japan K.K. | NCT04655092 Extension Study of P1101 After Completion of Phase 2 Study in PV Patients or Phase 3 Study in ET Patients | Polycythemia Vera (PV) | recruiting | 67 |
| 2026-06-30 est. | P2/P3 | Beacon Therapeutics BBT | NCT04850118 A Clinical Trial Evaluating the Safety and Efficacy of a Single Subretinal Injection of AGTC-501 in Participants With XLRP | X-Linked Retinitis Pigmentosa | active not recruiting | 85 |
| 2026-06-30 est. | P2 | Longeveron Inc. LGVN | NCT04925024 Evaluation of Lomecel-B™ Injection in Patients With Hypoplastic Left Heart Syndrome (HLHS): A Phase IIb Clinical Trial. | Hypoplastic Left Heart Syndrome | active not recruiting | 40 |
| 2026-06-30 | P1/P2 | Novita Pharmaceuticals, Inc. | NCT05023486 NP-G2-044 as Monotherapy and Combination Therapy in Patients With Advanced or Metastatic Solid Tumor Malignancies | Advanced or Metastatic Solid Tumor Malignancies | completed | 121 |
| 2026-06-30 est. | P1/P2 | TiumBio Co., Ltd. | NCT05204862 Phase 1/2 Study of TU2218 Alone and in Combination With Checkpoint Inhibitors in Patients With Advanced Solid Tumors | Advanced Solid Tumor | recruiting | 240 |
| 2026-06-30 est. | P2 | Curevo Inc | NCT05304351 Safety and Immunogenicity of CRV-101 Vaccine for the Prevention of Herpes Zoster in Adults Aged 50 Years and Older | Herpes Zoster; Shingles | active not recruiting | 1516 |
| 2026-06-30 est. | P3 | Shanghai Henlius Biotech | NCT05353257 A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cel | Limited-Stage Small Cell Lung Cancer | active not recruiting | 511 |
| 2026-06-30 est. | P1/P2 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | NCT05416775 Phase Ib/II Study of SHR-8068 Injection in the Treatment of Advanced Non-small Cell Lung Cancer | Advanced Non-small Cell Lung Cancer | unknown | 168 |
| 2026-06-30 est. | P1/P2 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | NCT05444088 Study of SHR-8068 Combined With Adebrelimab and Bevacizumab in the Treatment of Advanced Hepatocellular Carcinoma | Advanced Hepatocellular Carcinoma | unknown | 129 |
| 2026-06-30 est. | P3 | Celcuity Inc CELC | NCT05501886 Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer ( | Breast Cancer | active not recruiting | 701 |
| 2026-06-30 est. | P3 | Taizhou Hanzhong biomedical co. LTD | NCT05652894 A Study of HX008 Compared to Chemotherapy in the First-Line Treatment of Subjects With MSI-H/dMMR Metastatic Colorectal Cancer | Metastatic Colorectal Cancer | active not recruiting | 190 |
| 2026-06-30 est. | P3 | GC Biopharma Corp | NCT05686759 A Study to Investigate the Safety and Efficacy of Undiluted Intravenous Infusion of I.V.-Hepabig Inj. | Hepatitis B | recruiting | 105 |
| 2026-06-30 est. | P3 | Zenas BioPharma (USA), LLC ZBIO | NCT05786573 A Study of Obexelimab in Patients With Warm Autoimmune Hemolytic Anemia (SApHiAre) | Warm Autoimmune Hemolytic Anemia | active not recruiting | 134 |
| 2026-06-30 est. | P2 | AstraZeneca AZN | NCT05825365 Selumetinib in Chinese Paediatric With Post-operative NF1-PNs, PhaseⅡ, Double-Blinded, Placebo-Controlled Study | Neurofibromatosis Type 1; Plexiform Neurofibromas; Post-operative | withdrawn | |
| 2026-06-30 est. | P1/P2 | Akeso | NCT05904379 AK112 and AK104 With or Without Chemotherapy in Advanced Non-small Cell Lung Cancer | Advanced Non-small-cell Lung Cancer | active not recruiting | 233 |
| 2026-06-30 | P3 | Tenax Therapeutics, Inc. TENX | NCT05983250 LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF | Pulmonary Hypertension | active not recruiting | 230 |
| 2026-06-30 | P2 | AstraZeneca AZN | NCT06040099 A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular | Hepatocellular Carcinoma (HCC) | active not recruiting | 58 |
| 2026-06-30 est. | P1/P2 | GlaxoSmithKline | NCT06077877 A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Anticancer Activity of GSK4524101 Alone or With Niraparib in Participant | Neoplasms | active not recruiting | 42 |
| 2026-06-30 | P2 | Hillhurst Biopharmaceuticals, Inc. | NCT06144749 A Safety, Efficacy, and Pharmacokinetic (PK) Study of HBI-002, an Oral Carbon Monoxide (CO) Therapeutic, in Subjects With Sickle Cell Disease (SCD) | Anemia, Sickle Cell | completed | 13 |
| 2026-06-30 est. | P1/P2 | LaNova Medicines Limited | NCT06187402 A Study of LM-24C5 For Advanced Solid Tumors | Advanced Solid Tumor | recruiting | 49 |
| 2026-06-30 est. | P3 | Beijing Union Pharmaceutical Factory Ltd | NCT06243614 Phase Ⅲ Clinical Trial of Buagafuran Capsules in the Treatment of GAD | Generalized Anxiety Disorder | recruiting | 410 |
| 2026-06-30 est. | P3 | Beijing Union Pharmaceutical Factory Ltd | NCT06243640 Phase 3 Clinical Trial of Buagafuran Capsules in the Treatment of GAD | Generalized Anxiety Disorder | recruiting | 504 |
| 2026-06-30 est. | P2 | Keymed Biosciences Co.Ltd | NCT06372678 Study of CM326 in Participants With Chronic Rhinosinusitis With Nasal Polyposis | Chronic Rhinosinusitis With Nasal Polyps | unknown | 90 |
| 2026-06-30 | P2 | Ryvu Therapeutics SA | NCT06397313 RVU120 in Patients With Intermediate or High-risk, Primary or Secondary Myelofibrosis | Myelofibrosis | terminated | 36 |
| 2026-06-30 est. | P2 | LKGS_277 | NCT06410859 Botulinum Toxin Type A for Injection (HengLi®) in the Treatment of Trigeminal Neuralgia | Trigeminal Neuralgia | unknown | 240 |
| 2026-06-30 est. | P2/P3 | Tego Science, Inc. | NCT06414005 A Phase 2b/3 Study of TPX-115 on Partial-thickness Rotator Cuff Tear | Partial Thickness Rotator Cuff Tear | recruiting | 166 |
| 2026-06-30 est. | P2 | Qilu Pharmaceutical Co., Ltd. | NCT06446388 Study of QLS31905 and/or QL1706 Combination With Chemotherapy in the Advanced Malignant Solid Tumors | Advanced Solid Tumor | not yet recruiting | 360 |
| 2026-06-30 est. | P2 | Shenzhen TargetRx Co., Ltd. | NCT06453902 TGRX-678 Chinese Phase II in Chronic Myelogenous Leukemia (CML) Patients | Chronic Myeloid Leukemia; Accelerated Phase CML | recruiting | 40 |
| 2026-06-30 | P3 | GlaxoSmithKline | NCT06472076 A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) Hig | Lung Cancer, Non-Small Cell | active not recruiting | 88 |
| 2026-06-30 est. | P2 | Chengdu Zenitar Biomedical Technology Co., Ltd | NCT06485219 A Phase IIa Clinical Study of Purinostat Mesylate for Injection in Patients With Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma | Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL); Cutaneous T-cell Lymphoma (CTCL) | active not recruiting | 50 |
| 2026-06-30 est. | P2 | Shanghai Argo Biopharmaceutical Co., Ltd. | NCT06497127 A Study in Patients With Mixed Dyslipidemia | Mixed Dyslipidemia | active not recruiting | 145 |
| 2026-06-30 est. | P3 | Apnimed APMD | NCT06566820 Continuation Protocol for Obstructive Sleep Apnea (OSA) | OSA | enrolling by invitation | 1280 |
| 2026-06-30 est. | P1/P2 | Suzhou Puhe Pharmaceutical Technology Co., LTD | NCT06590194 PH009-1 in Patients With EGFR Mutation Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) | Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) | unknown | 96 |
| 2026-06-30 est. | P3 | Kexing Biopharm Co., Ltd. | NCT06711523 Study Evaluating PEG-G-CSF Injectionin Preventing Neutropenia After Chemotherapy | Neutropenia, Chemotherapy-Induced Febrile; Breast Neoplasm Female | active not recruiting | 250 |
| 2026-06-30 est. | P2 | NOBO Medicine | NCT06737250 NB02 (Poseltinib) Combined Rituximab and Lenalidomide in R/R PCNSL | Primary CNS Lymphoma (PCNSL) | recruiting | 33 |
| 2026-06-30 est. | P3 | Telix Pharmaceuticals (Innovations) Pty Limited TLX | NCT06750419 89Zr-TLX250 for PET/CT Imaging of ccRCC - ZIRCON-CP Study | Clear Cell Renal Cell Carcinoma | recruiting | 82 |
| 2026-06-30 est. | P1/P2 | Multitude Therapeutics Inc. | NCT06782334 AMT-116 in Patients with Solid Tumors | Advanced Solid Tumors | recruiting | 144 |
| 2026-06-30 est. | P2 | Shanghai Argo Biopharmaceutical Co., Ltd. | NCT06846398 A Phase 2 in Adult Subjects With Hereditary Angioedema | Hereditary Angioedema (HAE) | active not recruiting | 25 |
| 2026-06-30 est. | P1/P2 | Shanghai Institute Of Biological Products | NCT06932523 A Study to Evaluate the Safety of Recombinant Herpes Zoster Vaccine for Healthy Individuals | Herpes Zoster (HZ) | recruiting | 645 |
| 2026-06-30 est. | P1/P2 | Innovent Biologics (Suzhou) Co. Ltd. | NCT06974812 IBI3014 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors | Unresectable Locally Advanced or Metastatic Solid Tumors | recruiting | 250 |
| 2026-06-30 est. | P2 | Keymed Biosciences Co.Ltd | NCT07039578 Study Evaluating the Efficacy and Safety of CM336 Injection in the Treatment of Light-Chain Amyloidosis | Primary Light-Chain Amyloidosis | recruiting | 90 |
| 2026-06-30 est. | P3 | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. SBFM | NCT07042126 Evaluation of 611 in Chinese Adolescents With Moderate to Severe Atopic Dermatitis | Dermatitis, Atopic | recruiting | 180 |
| 2026-06-30 est. | P2 | Sirius Therapeutics Co., Ltd. SIRI | NCT07140523 A Study to Compare the Efficacy and Safety of SRSD107 and Enoxaparin in Adult Subjects Undergoing TKA | Venous Thromboembolism | recruiting | 450 |
| 2026-06-30 est. | P3 | Prime Gene Therapeutics Co., Ltd. | NCT07146126 A Phase III Study to Assess the Efficacy and Safety of PG-011 Nasal Spray in Adults With Moderate to Severe Seasonal Allergic Rhinitis | Seasonal Allergic Rhinitis; SAR | not yet recruiting | 600 |
| 2026-06-30 est. | P3 | Onconic Therapeutics Inc. | NCT07160790 Phase 3 Study of JP-1366: Efficacy and Safety of JP-1366 in Patients With Non-erosive Gastroesophageal Reflux Disease | Non-erosive Gastroesophageal Reflux Disease | not yet recruiting | 321 |
| 2026-06-30 est. | P3 | Laboratorios Sophia S.A de C.V. | NCT07305987 PRO-232 in Patients Subjected to Cataract Surgery | Cataract Extraction | recruiting | 134 |
| 2026-06-30 est. | P1/P2 | PT. Prodia Stem Cell Indonesia | NCT07429253 Secretome vs. PRP Injections for Hair Density and Growth in Androgenetic Alopecia Patients | Androgenetic Alopecia | recruiting | 40 |
| 2026-06-30 est. | P2 | Clarent Biopharma, Inc. | NCT07687966 CBP-0276 to Reduce Opioid Use in Adults Undergoing Major Orthopedic Surgery | Hip or Knee Replacement | recruiting | 80 |
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.